We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Cancer Biomarkers Detected Directly In Blood

By LabMedica International staff writers
Posted on 14 Aug 2013
A portable, microfluidics-based device has been developed for point-of-care diagnostic testing to detect cancer at its earliest stages. More...


The device identifies cancer biomarkers, which are biological indicators of the disease that often circulate in the blood prior to the appearance of symptoms.

Scientists at the Shanghai Institute of Microsystem and Information Technology (China) have developed a simple, power-free, whole blood, immunoassay, microfluidic system. The procedure integrates plasma extraction with on-chip nanoenzyme-linked immunosorbent assay (ELISA) for a highly sensitive immunoassay. This device uses a pre-degassed polydimethylsiloxane (PDMS) bulk containing mesh-shaped chambers as a suction pump to drive the fluid motion in the chip's microchannels during plasma separation and immunoassay. The system is powered by the pre-degassed bulk PDMS without using external power sources which would be useful for point-of-care diagnosis.

Carcino-embryonic antigen (CEA) and serum cytokeratin fragment 21-1 (CYFRA21-1) were used as model cancer biomarkers to demonstrate the ability of this system to directly detect these biomarkers in whole blood. To develop a simple and portable method, the investigators integrated the plasma separation and biomarker detection with microfluidic methods that combined ELISA and silver signal amplification. In contrast to most other microfluidic assays, they adopted reduction of silver ions onto gold nanoparticles in the ELISA procedure that allowed the signal to be amplified on a solid substrate under continuous fluid flow. The silver amplification readout was monitored using an optical microscope.

The authors concluded that the advantages of this biosensor over other currently available rapid tests for cancer biomarkers is that it can be operated without special equipment, with minimal training, and the cost of reagents is low. The device has potential for point-of-care applications because it is fast, disposable and easy to use and has a low sample volume and low cost. The device allows users to read results with the naked eye or a digital camera, eliminating the need for any expensive and complicated equipment, which makes it suitable for use in low technology, rural or field conditions.

Gang Li, PhD, a senior author of the study said, “Our device is well suited to helping early diagnosis in resource-limited settings where no mechanical pumps or power sources are readily available because it is portable, affordable, sensitive, and specific, and delivered by technology with a user-friendly analytical platform.” He noted that the specialized pump could be prepared in advance and stored in an airtight package. The study was published on May 23, 2013, in the journal Biomicrofluidics.

Related Links:

Shanghai Institute of Microsystem and Information Technology


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Hematology Analyzer
Medonic M32B
New
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.